Buy Strides Pharma Sciences; target of Rs 864: Sharekhan
Sharekhan is bullish on Strides Pharma Sciences recommended buy rating on the stock with a target price of Rs 864 in its research report dated October 29, 2020.
November 02, 2020 / 03:08 PM IST
Sharekhan's research repor on Strides Pharma Sciences
The results missed estimates. Revenues grew 11% YoY to Rs 793 crore while the adjusted PAT at Rs 44 crore declined by 9%. Strtides expects a marked improvement in its performance in 2HFY2021 as compared to 1HFY2021, driven by a sturdy growth across segments of regulated and emerging markets. Despite of a soft 1HFY21, Strides had retained its US revenue guidance of $230mn -$250 mn for FY21. Strong growth prospects and earnings visibility, sturdy balance sheet and healthy return ratios would support multiple re-ratings.
We retain Buy recommendation on Strides Pharma Science (Strides) with a PT of Rs 864. Q2FY2021 was a soft quarter for Strides.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.